SI1361864T1 - Kapljevite pršilne formulacije za bukalno administracijo kanabinoidov - Google Patents

Kapljevite pršilne formulacije za bukalno administracijo kanabinoidov

Info

Publication number
SI1361864T1
SI1361864T1 SI200231042T SI200231042T SI1361864T1 SI 1361864 T1 SI1361864 T1 SI 1361864T1 SI 200231042 T SI200231042 T SI 200231042T SI 200231042 T SI200231042 T SI 200231042T SI 1361864 T1 SI1361864 T1 SI 1361864T1
Authority
SI
Slovenia
Prior art keywords
cannabinoids
liquid spray
spray formulations
buccal delivery
buccal
Prior art date
Application number
SI200231042T
Other languages
English (en)
Slovenian (sl)
Inventor
Brian Whittle
Geoffrey Guy
Original Assignee
Gw Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27546617&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1361864(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0103638A external-priority patent/GB0103638D0/en
Priority claimed from US09/827,158 external-priority patent/US6730330B2/en
Priority claimed from GB0111597A external-priority patent/GB2377633A/en
Priority claimed from GB0121715A external-priority patent/GB2381194A/en
Priority claimed from US09/951,022 external-priority patent/US7025992B2/en
Application filed by Gw Pharma Limited filed Critical Gw Pharma Limited
Publication of SI1361864T1 publication Critical patent/SI1361864T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI200231042T 2001-02-14 2002-02-14 Kapljevite pršilne formulacije za bukalno administracijo kanabinoidov SI1361864T1 (sl)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB0103638A GB0103638D0 (en) 2001-02-14 2001-02-14 Pharmaceutical formulations
US28004401P 2001-03-30 2001-03-30
US09/827,158 US6730330B2 (en) 2001-02-14 2001-04-05 Pharmaceutical formulations
GB0111597A GB2377633A (en) 2001-05-11 2001-05-11 Pharmaceutical compositions comprising the cannabinoids THC and CBD
GB0121715A GB2381194A (en) 2001-09-07 2001-09-07 Pharmaceutical formulations
US09/951,022 US7025992B2 (en) 2001-02-14 2001-09-12 Pharmaceutical formulations
EP02712063.3A EP1361864B9 (fr) 2001-02-14 2002-02-14 Preparations de spray liquide pour l'administration buccale de cannabinoides
PCT/GB2002/000620 WO2002064109A2 (fr) 2001-02-14 2002-02-14 Preparations pharmaceutiques

Publications (1)

Publication Number Publication Date
SI1361864T1 true SI1361864T1 (sl) 2014-04-30

Family

ID=27546617

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200231042T SI1361864T1 (sl) 2001-02-14 2002-02-14 Kapljevite pršilne formulacije za bukalno administracijo kanabinoidov

Country Status (20)

Country Link
EP (5) EP1361864B9 (fr)
JP (1) JP4467883B2 (fr)
KR (1) KR100886668B1 (fr)
AU (1) AU2002231970B2 (fr)
CA (1) CA2438097C (fr)
CZ (1) CZ306277B6 (fr)
DE (1) DE10296335T5 (fr)
DK (1) DK1361864T3 (fr)
ES (1) ES2444641T3 (fr)
GB (1) GB2388543A (fr)
HK (1) HK1056509A1 (fr)
HU (1) HU227452B1 (fr)
IL (1) IL157130A0 (fr)
MX (1) MXPA03007215A (fr)
NO (1) NO334743B1 (fr)
NZ (1) NZ527289A (fr)
PT (1) PT1361864E (fr)
SI (1) SI1361864T1 (fr)
WO (1) WO2002064109A2 (fr)
ZA (1) ZA200306074B (fr)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2377633A (en) * 2001-05-11 2003-01-22 Gw Pharmaceuticals Ltd Pharmaceutical compositions comprising the cannabinoids THC and CBD
US10004684B2 (en) 2001-02-14 2018-06-26 Gw Pharma Limited Pharmaceutical formulations
GB2381194A (en) * 2001-09-07 2003-04-30 Gw Pharmaceuticals Ltd Pharmaceutical formulations
GB2381450B (en) * 2001-10-31 2006-05-31 Gw Pharma Ltd Compositions for administration of natural or synthetic cannabinoids by vaporisation
US8034843B2 (en) 2002-02-01 2011-10-11 Gw Pharma Limited Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions
GB0202385D0 (en) * 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
IL148244A0 (en) * 2002-02-19 2002-09-12 Yissum Res Dev Co Anti-nausea and anti-vomiting activity of cannabidiol compounds
DE10226494A1 (de) * 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
JP4657716B2 (ja) * 2002-08-14 2011-03-23 ジーダブリュー・ファーマ・リミテッド 植物材料からの薬学的に活性な成分の抽出の改良
GB2391865B (en) * 2002-08-14 2005-06-01 Gw Pharma Ltd Improvements in the extraction of pharmaceutically active components from plant materials
ATE533472T1 (de) 2002-08-14 2011-12-15 Gw Pharma Ltd Flüssige cannabinoid-formulierungen zur verabreichung an die schleimhäute
US7344736B2 (en) 2002-08-14 2008-03-18 Gw Pharma Limited Extraction of pharmaceutically active components from plant materials
GB2393182B (en) * 2002-09-23 2007-03-14 Gw Pharma Ltd Method of preparing cannabidiol from plant material
GB0222077D0 (en) 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
GB2394894B (en) * 2002-11-04 2005-08-31 G W Pharma Ltd New use for pharmaceutical composition
EP1644349B1 (fr) 2003-06-24 2014-04-09 GW Pharma Limited Compositions pharmaceutiques contenant des composes de type cannabichromene
ES2235626B1 (es) * 2003-11-10 2006-11-01 Almirall Prodesfarma, S.A. Formas de administracion masticables, no comprimidas dosificadas individualmente.
GB2414933B (en) * 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
GB2418612A (en) * 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
GB0425248D0 (en) * 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
EP1811983B1 (fr) * 2004-11-16 2020-10-07 GW Pharma Limited Nouvelle utilisation des cannabinoides
MX2007007038A (es) 2004-12-09 2008-03-07 Insys Therapeutics Inc Formulacion de dronabinol en temperatura ambiente.
GB2431105A (en) 2005-10-12 2007-04-18 Gw Pharma Ltd Cannabinoids for the treatment of pulmonary disorders
GB2432312A (en) * 2005-11-01 2007-05-23 Gw Pharma Ltd Pharmaceutical compositions for the treatment of pain
GB2434312B (en) 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
GB2439393B (en) * 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
US20100034888A1 (en) * 2006-09-15 2010-02-11 Hubert Clemens Pellikaan Granulate containing a pharmaceutically active substance and method for its manufacture
EP2063861B1 (fr) * 2006-09-15 2015-02-25 Echo Pharmaceuticals B.V. Unité posologique pour administration sublinguale, buccale ou orale de substances actives pharmaceutiques insolubles dans l'eau
AU2007302256A1 (en) 2006-09-27 2008-04-03 Niconovum Ab Directional use
GB2448535A (en) * 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
US9035130B2 (en) 2007-05-31 2015-05-19 Gw Pharma Limited Reference plant, a method for its production, extracts obtained therefrom and their use
GB2449691A (en) 2007-05-31 2008-12-03 Gw Pharma Ltd A reference plant lacking medicinal active compound expression
MY167918A (en) * 2009-04-23 2018-09-27 Londonpharma Ltd Composition for use in the sublingual delivery of medicaments to humans
JP5666574B2 (ja) 2009-06-29 2015-02-12 ベンデル・アナリティカル・ホールディング・ビー．ブイ．Ｂｅｎｄｅｒ Ａｎａｌｙｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｂ．Ｖ． ポリオキサゾリンおよび生物活性物質を含む薬物送達システム
GB2471523A (en) * 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
AT509000B1 (de) * 2009-10-23 2012-12-15 Rausch Peter Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen
GB2479153B (en) * 2010-03-30 2014-03-19 Gw Pharma Ltd The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
US8529914B2 (en) * 2010-06-28 2013-09-10 Richard C. Fuisz Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2524689B (en) * 2011-05-20 2016-01-27 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
GB201111261D0 (en) 2011-07-01 2011-08-17 Gw Pharma Ltd Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB201117956D0 (en) * 2011-10-18 2011-11-30 Otsuka Pharma Co Ltd Phytocannabinoids for use in the treatment of breast cancer
GB2496688B (en) * 2011-11-21 2016-06-29 Gw Pharma Ltd Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases
US9776014B2 (en) 2012-05-03 2017-10-03 Magdent Ltd. Bone enhancement device and method
JP2015521175A (ja) 2012-05-07 2015-07-27 エコ・ファーマシューティカルズ・ビー．ブイ．Ｅｃｈｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｂ．Ｖ． カンナビノイド含有粒状体、その製造方法、及びこのような粒状体を含む経口投与単位
US9199960B2 (en) 2013-05-02 2015-12-01 Frederick R. Ferri Method and apparatus for processing herbaceous plant materials including the cannabis plant
US9333229B2 (en) * 2013-10-16 2016-05-10 William Bjorncrantz Winterized crude cannabis extracts and methods of preparation and use
US9616025B2 (en) 2013-10-29 2017-04-11 Echo Pharmaceuticals B.V. Compressed tablet containing Δ9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment
CA2929321C (fr) 2013-10-29 2022-04-05 Echo Pharmaceuticals B.V. Pastille comprimee comprenant du cannabidiol, son procede de fabrication, et utilisation d'une telle pastille pour le traitement oral de troubles de psychose ou d'anxiete
US11033493B2 (en) * 2013-12-02 2021-06-15 Intelgenx Corp. Film dosage form with extended release mucoadhesive particles
US9186386B2 (en) 2014-04-17 2015-11-17 Gary J. Speier Pharmaceutical composition and method of manufacturing
US9044390B1 (en) 2014-04-17 2015-06-02 Gary J. Speier Pharmaceutical composition and method of manufacturing
WO2015184127A2 (fr) 2014-05-29 2015-12-03 Insys Pharma, Inc. Formulations de cannabinoïdes stables
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
AU2015292915B2 (en) * 2014-07-21 2020-10-15 Pharmaceutical Productions, Inc. Solid dosage form composition for buccal or sublingual administration of cannabinoids
CA2961410C (fr) 2014-09-16 2023-07-11 India Globalization Capital, Inc. Composition cannabinoide et methode de traitement de la douleur
US9844518B2 (en) 2014-09-30 2017-12-19 MJAR Holdings, LLC Methods of growing cannabaceae plants using artificial lighting
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
US9730911B2 (en) 2014-10-21 2017-08-15 United Cannabis Corp. Cannabis extracts and methods of preparing and using same
WO2016118391A1 (fr) 2015-01-25 2016-07-28 India Globalization Capital, Inc. Compositions et procédés de traitement de troubles épileptiques
WO2016126592A1 (fr) 2015-02-02 2016-08-11 Axim Biotechnologies, Inc. Complexe de cannabinoïdes et d'alcools de sucre et ses procédés de fabrication et d'utilisation
EP3277260B1 (fr) 2015-04-01 2021-05-12 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) Extraits végétaux de crassifolium erodium l'her et leurs utilisations
WO2016191651A1 (fr) * 2015-05-28 2016-12-01 Insys Development Company, Inc. Formulations de cannabinoïdes stables
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US10751320B2 (en) 2015-07-08 2020-08-25 Flavocure Biotech, Llc Therapeutic agents containing cannabis flavonoid derivatives for the prevention and treatment of neurodegenerative disorders
US10456435B2 (en) 2015-07-15 2019-10-29 Christopher A. MCELVANY Topical antiviral formulations and methods of using the same
US10092855B2 (en) 2015-07-16 2018-10-09 Fritz Chess CO2 extraction and filtration system
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
WO2017027651A1 (fr) 2015-08-12 2017-02-16 India Globalization Capital, Inc. Méthode et composition pour traiter la cachexie et les troubles de l'alimentation
WO2017066474A1 (fr) * 2015-10-15 2017-04-20 Preleve Therapeutics, Llc Compositions et procédés destinés à soulager la douleur
IL244278A0 (en) * 2016-02-24 2016-07-31 Cannabics Pharmaceuticals Inc An ingredient containing cannabinoids, methods for its preparation and its uses
ITUB20161247A1 (it) * 2016-03-02 2017-09-02 Labomar S R L Compressa orodispersibile contenente un principio attivo liposolubile
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
EP3445838B1 (fr) 2016-04-18 2023-05-10 Gene Pool Technologies, Inc. Isolement d'extraits de plantes
JP6983868B2 (ja) 2016-04-22 2021-12-17 レセプター・ホールディングス・インコーポレイテッド 即効性の植物由来医薬化合物及び栄養補給剤
EP3463287A1 (fr) 2016-05-27 2019-04-10 MedCan Pharma A/S Composition pulvérulente comprenant un complexe entre un cannabinoïde et une résine d'échange d'ions basique
US20170348276A1 (en) * 2016-06-02 2017-12-07 Acerus Pharmaceutical Corporation Nasal cannabidiol compositions
EP3471746A4 (fr) 2016-06-15 2020-02-26 India Globalization Capital, Inc. Méthode et composition pour traiter des troubles epileptiques
US10765658B2 (en) 2016-06-22 2020-09-08 Mastix LLC Oral compositions delivering therapeutically effective amounts of cannabinoids
JP2019524655A (ja) 2016-06-29 2019-09-05 キャンサイエンス イノベーションズ インコーポレーテッドＣａｎｎｓｃｉｅｎｃｅ Ｉｎｎｏｖａｔｉｏｎｓ Ｉｎｃ． 脱炭酸大麻樹脂、その使用、及びそれを製造する方法
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
PE20200478A1 (es) * 2016-07-25 2020-03-03 Canopy Growth Corp Nuevas formulaciones y composiciones de cannabis en comprimidos y metodos para su elaboracion
US9833408B1 (en) * 2016-07-28 2017-12-05 Allen Greenspoon Orally administrable formulation
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
EP3558297A1 (fr) * 2016-12-20 2019-10-30 Tilray, Inc. Nouvelles compositions de cannabinoïdes et méthodes de traitement de l'épilepsie pédiatrique
AU2018210690B2 (en) * 2017-01-23 2020-12-03 CannTab Therapeutics Limited Immediate release cannabidiol formulations
WO2019036243A1 (fr) * 2017-08-16 2019-02-21 Molecular Infusions, Llc Formulations
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
CA3055060A1 (fr) 2017-03-05 2018-09-13 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Compositions et methodes pour le traitement du cancer
US10596485B2 (en) 2017-04-03 2020-03-24 Fritz Chess Multi-functional distiller
US10058531B1 (en) 2017-06-01 2018-08-28 Spartak LLC Dosage delivery film
WO2019003226A1 (fr) * 2017-06-27 2019-01-03 Panaxia Pharmaceutical Industries Ltd. Combinaison de cannabinoïdes et d'au moins un ingrédient supplémentaire pour l'amélioration de la puissance thérapeutique
WO2019055118A2 (fr) * 2017-07-13 2019-03-21 Tab Protein, Llc Comprimé d'aliment de complément et emballage
US20200281890A1 (en) * 2017-09-25 2020-09-10 Canopy Health Innovations Compositions comprising cannabidiol, tetrahydrocannabinol, terpenes, and flavonoids and use thereof in the treatment of insomnia
US10220061B1 (en) 2017-09-26 2019-03-05 Cynthia Denapoli Method of reducing stress and anxiety in equines
CN111225678A (zh) * 2017-10-05 2020-06-02 受体控股公司 快速起效且延长作用的植物类及合成大麻素制剂
GB2567240B (en) 2017-10-09 2022-04-06 Senzer Ltd An inhaler particularly a cannabinoid inhaler and a method of assembling such an inhaler
MX2020005697A (es) * 2017-12-01 2020-10-28 Healthy Option Consulting Inc Capsula blanda de gel liquido de doble camara y metodo para administrar composiciones de cannabis sublinguales e ingeribles.
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
BR112020014253A2 (pt) 2018-01-12 2020-12-08 Nutrae, LLC Formulações de canabinóides encapsuladas para administração oral
WO2019159185A1 (fr) 2018-02-19 2019-08-22 To Pharmaceuticals Llc Compositions et méthodes pour le traitement de l'atrophie d'énergie des protéines
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
SI25373A (sl) * 2018-05-08 2018-08-31 Danijela Marković Naravna orodisperzibilna tableta
KR20210040282A (ko) 2018-05-11 2021-04-13 로드스 테크놀로지즈 경구 전달용 조성물 및 투여 형태
GB201807801D0 (en) 2018-05-14 2018-06-27 Plantine Holdings Ltd Microparticles
CN112672740A (zh) * 2018-06-15 2021-04-16 康宝动物治疗有限公司 大麻素组合物以及使用大麻素组合物的治疗方法
US11439595B2 (en) 2018-07-18 2022-09-13 Glatt Gmbh Immediate release formulations of cannabinoids
CA3114249A1 (fr) * 2018-09-26 2020-04-02 Hexo Operations Inc. Concentre contenant un cannabinoide pour la fabrication d'un produit destine a la consommation humaine et presentant un profil de gout ameliore, et procedes de fabrication corresp ondants
CA3138732A1 (fr) * 2018-11-30 2020-06-04 Canopy Growth Corporation Formulations de cannabinoides ou de composes derives du cannabis solubles dans l'eau, methode de fabrication et utilisation
DE102019100483A1 (de) * 2019-01-10 2020-07-16 Lts Lohmann Therapie-Systeme Ag Oraler Dünnfilm
US11147805B2 (en) 2019-02-07 2021-10-19 Medipure Pharmaceuticals Inc. Cannabinoid receptor agonists and serine hydrolase enzyme inhibitor based anxiolytic therapeutic product
CA3040547C (fr) * 2019-04-17 2021-12-07 Medcan Pharma A/S Formulation de pastille de cannabinoide
US20200360292A1 (en) * 2019-05-16 2020-11-19 Aegis Therapeutics, Llc Oil-soluble drug containing compositions and methods of use thereof
DE102019211195A1 (de) * 2019-07-26 2021-01-28 Add Advanced Drug Delivery Technologies Ltd. Verfahren und Vorrichtung zur Herstellung eines im Wesentlichen im wässrigen Milieu lösbaren Cannabinoid-Granulats
CN114245739A (zh) * 2019-08-12 2022-03-25 腾思凯真私人有限公司 大麻二酚口腔崩解片
AU2020335245A1 (en) 2019-08-30 2022-03-10 Evie Sa Loaded granules, their process of production and their uses
CN110604195A (zh) * 2019-09-10 2019-12-24 普洱茶王茶业集团股份有限公司 一种普洱茶保健饮品及其制备方法
CA3154616A1 (fr) * 2019-09-20 2021-03-25 Mycotechnology, Inc. Procedes pour la reduction de l'amertume dans des cannabinoides a l'aide de materiels myceliens
EP3808341A1 (fr) * 2019-10-16 2021-04-21 ADD Advanced Drug Delivery Technologies, Ltd. Formulations à libération contrôlée des substances actives physiologiques très lipophiles
US20220387376A1 (en) * 2019-10-18 2022-12-08 Natural Extraction Systems, LLC Compositions Comprising Cannabinoid Molecules that are Dissolved in Water-Miscible Solvents
WO2021116824A1 (fr) * 2019-12-09 2021-06-17 Nicoventures Trading Limited Produit à usage oral comprenant un cannabinoïde
CA3160750A1 (fr) 2019-12-09 2021-06-17 Anthony Richard Gerardi Produit a usage oral comprenant un cannabinoide
EP4072518A1 (fr) * 2019-12-09 2022-10-19 Nicoventures Trading Limited Produit à usage oral comprenant un cannabinoïde
WO2021116826A1 (fr) * 2019-12-09 2021-06-17 Nicoventures Trading Limited Produit à usage oral comprenant un cannabinoïde
WO2021151212A1 (fr) * 2020-01-31 2021-08-05 Hexo Operations Inc. Système et procédé de quantification, de formulation et d'amélioration du profil d'expérience utilisateur du cannabis
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
EP4157260A4 (fr) * 2020-06-01 2024-05-22 Technion Res & Dev Foundation Compositions et procédés de traitement de maux de tête
GB2595692A (en) 2020-06-03 2021-12-08 Senzer Ltd A refill for an inhaler particularly a cannabinoid inhaler
EP4188090A2 (fr) 2020-07-28 2023-06-07 Impello Biosciences, Inc. Procédés et compositions pour modifier des métabolites secondaires dans des plantes
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
WO2022085622A1 (fr) 2020-10-23 2022-04-28 富士カプセル株式会社 Capsule molle sans raccord contenant du cannabidiol
US11839602B2 (en) 2020-11-25 2023-12-12 Nicoventures Trading Limited Oral cannabinoid product with lipid component
US20240066041A1 (en) 2021-03-26 2024-02-29 Anabio Technologies Limited Microparticles containing stabilized cbd oil, and methods for the production thereof
WO2023275864A1 (fr) * 2021-06-27 2023-01-05 Roxx Labs Ltd. Procédé de préparation de compositions cannabinoïdes aqueuses
EP4134073A1 (fr) 2021-08-11 2023-02-15 HM HerbaMedica GmbH Compositions pharmaceutiques comprenant des nanoporteurs dendritiques et des agents actifs de cannabis
WO2023144340A1 (fr) 2022-01-28 2023-08-03 Vertanical GmbH Procédé de production d'un extrait de plante
US20240024253A1 (en) * 2022-07-21 2024-01-25 Pike Therapeutics Inc. Continuous Drug Delivery Systems and Methods

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3504384A (en) 1963-10-23 1970-04-07 Russell Research Ltd Toilet bowl cleaning and disinfecting device
US3560625A (en) 1967-02-20 1971-02-02 Colgate Palmolive Co Method of,and formulations for,introducing alkoxybenzamides into the systemic circulatory system
GB1466560A (en) 1974-02-05 1977-03-09 Jeyes Group Ltd Bleach compositions
US4248827A (en) 1978-06-12 1981-02-03 The Procter & Gamble Company Method for sanitizing toilets
US4200606A (en) 1978-12-22 1980-04-29 The Procter & Gamble Company Method for sanitizing toilets
GB8325541D0 (en) 1983-09-23 1983-10-26 Unilever Plc Liquid thickened bleaching composition
DE3419169A1 (de) 1984-05-23 1985-11-28 Henkel KGaA, 4000 Düsseldorf Dosiervorrichtung
GB8603300D0 (en) 1986-02-11 1986-03-19 Unilever Plc Bleaching composition
US5034150A (en) 1989-05-03 1991-07-23 The Clorox Company Thickened hypochlorite bleach solution and method of use
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy
NL9101759A (nl) 1991-10-22 1993-05-17 Sara Lee De Nv Vloeibaar-reinigings- en/of verfrissingsmiddel voor een toiletpot.
GB2285921A (en) * 1994-01-31 1995-08-02 Leilani Lea Sublingual administration of medicaments
CA2185803C (fr) * 1994-03-18 2006-07-11 Edward M. Rudnic Systemes d'administration de medicaments emulsionnes
US5540934A (en) 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
NL1001722C2 (nl) 1995-11-22 1997-05-23 Sara Lee De Nv Reinigings- en verfrissingseenheid bestemd om te worden opgehangen aan een toiletpotrand.
EP0775741A1 (fr) 1995-11-22 1997-05-28 Sara Lee/DE N.V. Système de nettoyage/rafraichissement de WC
US5891465A (en) * 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
US5891469A (en) * 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
US6113940A (en) * 1997-03-03 2000-09-05 Brooke; Lawrence L. Cannabinoid patch and method for cannabis transdermal delivery
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
US6630507B1 (en) * 1998-04-21 2003-10-07 The United States Of America As Represented By The Department Of Health And Human Services Cannabinoids as antioxidants and neuroprotectants
JP2002513750A (ja) * 1998-05-07 2002-05-14 エラン コーポレーシヨン ピーエルシー 溶媒／助溶剤を含まないマイクロエマルジョン及びエマルジョンプレ濃縮物のドラッグデリバリーシステム
CA2334793C (fr) 1998-06-15 2006-12-12 S. C. Johnson & Son, Inc. Distribution de liquides pour rebord de toilette
GB2338495B (en) 1998-06-15 2000-08-09 Johnson & Son Inc S C A unit for dispensing a liquid from the rim of a lavatory bowl
US6365416B1 (en) * 1998-10-26 2002-04-02 The University Of Mississippi Method of preparing delta-9-tetrahydrocannabinol
DE19912217C2 (de) 1999-01-12 2002-09-05 Jeyes Deutschland Gmbh Vorrichtung zur Abgabe von Wirkstoffen in das Spülwasser insbesondere in Toilettenbecken
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
CA2341035A1 (fr) * 1999-07-08 2001-01-18 Orlando Hung Administration pulmonaire de cannabinoides encapsules dans des liposomes
AU1160301A (en) 1999-11-02 2001-05-14 Jeyes Group Limited Liquid delivery devices
SI1280515T1 (sl) * 2000-03-09 2007-06-30 Gw Pharma Ltd Farmacevtski sestavki, ki vsebujejo kanabis
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
GB2368576A (en) 2000-11-02 2002-05-08 Brian Parry Slade Liquid delivery device having a layer of textile material
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
US20050079136A1 (en) * 2001-07-10 2005-04-14 Woolfe Austen John Aerosol formulations of delta tetrahydrocannabinol

Also Published As

Publication number Publication date
EP2298283A2 (fr) 2011-03-23
EP2286793A3 (fr) 2014-01-08
KR100886668B1 (ko) 2009-03-04
HU227452B1 (en) 2011-06-28
IL157130A0 (en) 2004-02-08
JP2005512943A (ja) 2005-05-12
CA2438097C (fr) 2006-04-25
HUP0303182A2 (hu) 2003-12-29
HK1056509A1 (en) 2004-02-20
DK1361864T3 (en) 2014-03-03
AU2002231970B2 (en) 2007-08-16
GB0319041D0 (en) 2003-09-17
EP2292211A3 (fr) 2014-01-01
JP4467883B2 (ja) 2010-05-26
EP2298284A2 (fr) 2011-03-23
KR20030074835A (ko) 2003-09-19
ZA200306074B (en) 2005-01-26
ES2444641T3 (es) 2014-02-26
EP1361864B9 (fr) 2014-07-09
CA2438097A1 (fr) 2002-08-22
EP1361864A2 (fr) 2003-11-19
GB2388543A (en) 2003-11-19
EP2286793A2 (fr) 2011-02-23
CZ20032458A3 (cs) 2003-11-12
PT1361864E (pt) 2014-03-03
EP2298284A3 (fr) 2013-12-18
WO2002064109A3 (fr) 2003-02-20
DE10296335T5 (de) 2004-04-15
WO2002064109A2 (fr) 2002-08-22
CZ306277B6 (cs) 2016-11-09
EP2292211A2 (fr) 2011-03-09
EP1361864B1 (fr) 2013-12-04
NZ527289A (en) 2005-05-27
MXPA03007215A (es) 2003-12-04
NO20033556D0 (no) 2003-08-11
NO334743B1 (no) 2014-05-19
EP2298283A3 (fr) 2012-12-26
NO20033556L (no) 2003-10-09

Similar Documents

Publication Publication Date Title
HK1056509A1 (en) Liquid spray formulations for buccal delivery of cannabinoids
IL161214A0 (en) Compositions for delivery of drug combinations
EP1416884A4 (fr) Administration d'agents potentiellement therapeutiques
IL162294A0 (en) Formulation & dosage form for the controlled delivery of therapeutic agents
IL161446A0 (en) Medicinal compositions for nasal absorption
HUP0401514A3 (en) Pharmaceutical compositions for the treatment of asthma
HUP0302847A3 (en) Pharmaceutical formulation comprising bicalutamide
EG24078A (en) Liquid pharmaceutical composition
IL159722A0 (en) Pharmaceutical compositions containing oligonucleotides
GB0122725D0 (en) Drug dispensing components
EP1663783A4 (fr) Systeme de distribution de liquide de masque a gaz
IL160375A0 (en) Pharmaceutical compositions comprising lumiracoxib
IL158255A0 (en) Compositions containing imidazotriazinone for nasal application
HK1064953A1 (en) Compositions for nasal administration of insulin
IL161902A0 (en) Pharmaceutical formulation comprising bicalutamide
IL161306A0 (en) Pharmaceutical formulation comprising (r)-bicalutamide
AU2002240942A1 (en) Improved delivery of benefit agents
GB2378186B (en) Mild antimicrobial liquid cleansing formulations
IL158172A0 (en) Pharmaceutical compositions containing (-)-hydroxycitric acid
HUP0200253A2 (en) Pharmaceutical compositions for combination therapy
GB2385115B (en) Liquid Dispensing Nozzle
HUP0103049A3 (en) Use of fluexetine for preparation of pharmaceutical compositions
GB0114844D0 (en) Formulation delivery
GB0124010D0 (en) Pharmaceutical compositions for inhalation
GB0127359D0 (en) Pharmaceutical compositions for inhalation